Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ProMIS Neurosciences Inc
PMN
Healthcare
Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine...
applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PMN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(81)
•••
goldtech
X
View Profile
View Bullboard History
Comment by
goldtech
on Apr 26, 2024 7:39pm
RE:RE:The only scenario
Partnership, joint venture, collaboration, call it what you want but if we succeed then credits will be afforded to the entire platform. This all stems on the two scenarios and if successful, big
...more
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Apr 26, 2024 5:09pm
RE:The only scenario
Is that from your belief about Boston Group's ROI timeline or why else do you rule out any sort of partnership, equity swap, license deal etc.? I disagree regardless because I don'
...more
New PEA Indicates an Ultra Low-Cost Uranium Project with Huge Exploration Upside
posted Apr 26, 2024 9:00am by
Blue Sky Uranium Corp
-
|
This PEA reaffirms that the deposit is a leading low-cost uranium-vanadium project. We believe that this resurgent uranium market has a strong long-term outlook and we are therefore preparing to complete a prefeasibility study as soon as possible ...read more
(81)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Apr 26, 2024 4:53pm
The only scenario
There is only two outcomes, success with the antibody or failure, end of story. If they succeed, instant buyout, if not, and empty public shell. Now everything points to an interesting outcome.
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on Apr 26, 2024 4:09pm
@ the Bell: Despite earlier struggles, TSX finishes the week higher
The mining sector was the biggest gainer on the TSX while declines in the energy sector offered the most drag.
read article.
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Apr 26, 2024 1:30pm
RE:RE:Bottom line
Or, (and this is an analogy so don't censor me again) instead of talking about how we modified the trial protocol to appease the dog humpers, we start talking about how many years ago we told them
...more
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Apr 26, 2024 1:16pm
RE:Bottom line
Lol, not likely. Once you meet a bully's first condition you don't get respect, you get the next condition.
(81)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Apr 26, 2024 11:38am
Bottom line
So if we assume that the timeline and present data is correct , then by June 2025 we will be in a bidding war for PMN. Show that you can achieve efficacy without Aria E and Big pharma will be at the
...more
(118)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Apr 26, 2024 5:47am
RE:RE:RE:No News
Hoping for a lower dose of PMN-310 to be successful enough that could lead to subcutaneous (injection) dosing of AZ patients in place of intravenous. Makes it easier for patients and presumable less
...more
(1)
•••
farmerlucy
X
View Profile
View Bullboard History
Post by
farmerlucy
on Apr 25, 2024 8:43pm
Promisneuroscience News
Promis presented yesterday in Boston at the Alzheimers and Parkinson's drug development summit. Cashman presented and was on a panel. Interesting to see on the front page attentding companies
...more
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Apr 25, 2024 6:36pm
RE:RE:RE:RE:No News
And btw, I don't think they have anything to lose by attacking big pharma on multiple fronts. Money has no feelings.
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Apr 25, 2024 6:29pm
RE:RE:RE:No News
Perhaps Goldtech will enlighten us all as to what a winning argument might be for such a hypothetically endowed company?
(81)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Apr 25, 2024 6:02pm
RE:RE:No News
PMN310 stands out from the competition in vitro. The original Acumen publication cited some anomalies for non-target binding to plaque, and I always thought it was strange that those
...more
(13)
•••
garygp
X
View Profile
View Bullboard History
Comment by
garygp
on Apr 25, 2024 4:38pm
RE:RE:No News
I think goldtech was meaning more along the lines of business acumen, meaning the ability of management to think quickly, ability to make sound business decisions and act on them, and not Acumen
...more
(118)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Apr 25, 2024 3:46pm
RE:No News
What is important about bringing Acumen to the discussion is that we now know that Acumen also binds plaque attributing to the ERIA-E-related brain swelling side effects. However, we don't know
...more
(81)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Apr 25, 2024 3:02pm
No News
This company has never ever had the stock acumen needed to attract shareholder appreciation and awareness. Wake up management!!!!!
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on Apr 25, 2024 4:58am
Buzz on the Bullboards: A recap of recent activity and stocks in focus
After a major sell-off, stock markets have been on edge, monitoring corporate earnings to gauge the direction of the economy.
read article.
(81)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Apr 22, 2024 10:42pm
RE:Bloom Burton Conference
Thanks Bball. I thought the Q&A showed a high level of engagement and curiosity from the audience. The questions were very specific, indicating that the audience had been doing their
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Centurion Identifies High Quality Gold Target-Casa Berardi West Project; Acquires Additional Claims
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study
Two New Contracts Awarded Covering Five Onshore Fields Producing 3,000 bbl/d of Oil
Fresh Insight into the Topaz HELIUM Project's Expected Size and Scale
Exploration company provides project portfolio update